Illumina, Inc. vs Ralph Lauren Corp — how do they compare? Illumina, Inc. trades at $266.99 (market cap $39.95B), while Ralph Lauren Corp trades at $368.77 (market cap $21.89B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Ralph Lauren Corp pays a 1.09% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Ralph Lauren Corp for 84 Days on average.
| ILMN | RL | |
|---|---|---|
Market Cap | $39.95B | $21.89B |
Volume | 3,169,503 | 481,617 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $414.25 |
52-Week Low | $91.00 | $309.29 |
Typical Hold Time | 83 Days | 84 Days |
Enterprise Value | $41.31B | $22.95B |
Dividend Yield | — | 1.09% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Ralph Lauren (RL) trades at $361.14, down 2.04% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.59 exceeding the $4.32 estimate. Revenue growth has accelerated from $6.2B in 2022 to $7.1B in 2025, while net income margins improved to 10.49%. Recent developments include global store expansion and sustainability initiatives under the Timeless by Design 2030 strategy.
RL presents a compelling investment case with strong profitability (37.54% ROE, 70.27% gross margins) and analyst consensus pointing to 26% upside to the $456.67 price target. However, the stock faces near-term technical headwinds and competitive pressures in the luxury apparel sector. The improving cash flow trajectory and dividend payments provide shareholder value support amid market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →